Skip to main navigation menu Skip to main content Skip to site footer

No. 1 (2026)

GENERAL THERAPY QUESTIONS AND REVIEWS

Strategies for the Prevention and Treatment of Mental Disorders in Patients with Neurofibromatosis Type 1

https://doi.org/10.48612/psyph/tzvv-r257-ph86

Published 2026-03-30

  • R.N. Mustafin
    • ,
  • E.A. Galieva

R.N. Mustafin
Bashkir State Medical University

E.A. Galieva
Ufa University of Science and Technology

Abstract

Background. Neurofibromatosis type 1 (NF1) is a common autosomal dominant monogenic disorder, characterized by the development of multiple tumors and malignancies. Most patients with NF1 develop various mental disorders (MDs), the classification of which into categories is relevant for their diagnosis, prevention, and treatment by specialists.

Aim — to determine the types of MDs, their frequency and most effective prevention and treatment strategies in patients with NF1.

Methods. An analysis of scientific literature in the Scopus, Web of Science, and eLIBRARY.RU databases on a given topic was conducted. From 965 publications, 63 studies were selected.

Results. Causes of MDs in patients with NF1 include brain damage due to the pathogenesis of the disease, psychological distress caused by disfiguring manifestations of the disease, and a lack of information about available treatment options for tumor syndrome. The prevalence of MDs in this patient group is significantly higher than in the general population. To prevent MDs, all NF1 patients should receive consultations with psychologists and psychiatrists after diagnosis. Patients should be informed about the possibility of removing multiple cutaneous neurofibromas with a surgical laser, the effectiveness of targeted therapy for plexiform neurofibromas, and the prevention of NF1 transmission to children. The treatment of MDs in patients with NF1 follows strategies according to clinical guidelines (pharmacotherapy depending on MD type).

Conclusions. An important factor in MD’s preventing in NF1 patients is awareness of available modern treatments for the tumor syndrome, which instills confidence and improves quality of life. Due to frequent MDs development in NF1 patients, consultations with psychologists and psychiatrists are necessary for early diagnosis and treatment of MDs in accordance with clinical guidelines.

Keywords

depressive disorders, quality of life, neurofibromatosis type 1, neurofibromas, mental disorders, anxiety disorders

PDF (Русский)

References

  1. Lee T.J., Chopra M., Kim R.H. et al. Incidence and prevalence of neurofibromatosis type 1 and 2: A systematic review and meta-analysis // Orphanet J Rare Dis. – 2023. – Vol. 18 (1). – Art. 292. – https://doi.org/10.1186/s13023-023-02911-2
  2. Miraglia E., Moliterni E., Iacovino C. et al. Cutaneous manifestations in neurofibromatosis type 1 // Clin Ter. – 2020. – Vol. 171 (5). – Pp. e371–e377. – https://doi.org/10.7417/CT.2020.2242
  3. Ly K.L., Blakeley J.O. The diagnosis and management of neurofibromatosis type 1 // Med Clin North Am. – 2019. – Vol. 103. – Pp. 1035–54. – https://doi.org/10.1016/j.mcna.2019.07.004
  4. Copley-Merriman C., Yang X., Juniper M. et al. Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: A systematic literature review // Adolesc Health Med Ther. – 2021. – Vol. 12. – Pp. 55–66. – https://doi.org/10.2147/AHMT.S303456
  5. Lim Z., Gu T.Y., Tai B.C. et al. Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): A meta-analysis // World J Surg Oncol. – 2024. – Vol. 22 (1). – Art. 14. – https://doi.org/10.1186/s12957-023-03296-z
  6. Uusitalo E., Rantanen M., Kallionpää R.A. et al. Distinctive cancer associations in patients with neurofibromatosis type 1 // J Clin Oncol. – 2016. – Vol. 34 (17). – Pp. 1978–86. – https://doi.org/10.1200/JCO.2015.65.3576
  7. Wang D., Zhang B.H., Wen X. et al. Clinical features and surgical treatments of scoliosis in neurofibromatosis type 1: A systemic review and meta-analysis // Eur Spine J. – 2024. – Vol. 33 (7). – Pp. 2646–2665. – https://doi.org/10.1007/s00586-024-08194-w
  8. Genc A., Ünal Y., Ceylan A.C. et al. Clinical and molecular characterization of 148 pediatric neurofibromatosis type 1 patients: A single-center study identifying 14 novel variants // Eur J Pediatr. – 2025. – Vol. 184 (12). – Art. 751. – https://doi.org/10.1007/s00431-025-06611-w
  9. Glombova M., Petrak B., Lisy J. et al. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1 // Brain Dev. – 2019. – Vol. 41 (8). – Pp. 678–90. – https://doi.org/10.1016/j.braindev.2019.04.003
  10. Wu F., Ji X., Shen M. et al. Prevalence, clinical characteristics and outcomes of seizures in neurofibromatosis type 1: A systematic review and single arm meta-analysis // Epilepsy Res. – 2024. – Vol. 208. – Art. 107476. – https://doi.org/10.1016/j.eplepsyres.2024.107476
  11. Al-Farsi F.A.H., Al-Alyani O.B.S., Al-Kumzari A. et al. Systemic review and meta-analysis of the intellectual integrity of children with neurofibromatosis type 1 // World Neurosurg. – 2022. – Vol. 157. – Pp. 69–74. – https://doi.org/10.1016/j.wneu.2021.10.081
  12. Мустафин Р.Н. Особенности хирургического лечения нейрофиброматоза I типа // Российский журнал детской гематологии и онкологии. – 2022. – Т. 9 (2). – С. 54–59. – https://doi.org/10.21682/2311-1267-2022-9-2-54-59
  13. Han Y., Li B., Yu X. et al. Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: A systematic review and meta-analysis // J Neurol. – 2024. – Vol. 271 (5). – Pp. 2379–2389. – https://doi.org/10.1007/s00415-024-12301-8
  14. Мустафин Р.Н. Возможности диагностики и лечения нейрофиброматоза 1-го типа в России // Сибирский онкологический журнал. – 2023. – Vol. 22 (3). – C. 119–124. – https://doi.org/10.21294/1814-4861-2023-22-3-119-124
  15. Vranceanu A.M., Zale E.L., Funes C.J. et al. Mind-body treatment for international English-speaking adults with neurofibromatosis via live videoconferencing: Protocol for a single-blind randomized controlled trial // JMIR Res Protoc. – 2018. – Vol. 7 (10). – e11008. – https://doi.org/10.2196/11008
  16. Lester E.G., Hopkins S.W., Popok P.J. et al. Adaptation of a live video mind-body program to a web-based platform for English-speaking adults with neurofibromatosis: Protocol for the NF-web study // JMIR Res Protoc. – 2021. – Vol. 10 (6). – e27526. – https://doi.org/10.2196/27526
  17. Wolkenstein P., Rodriguez D., Ferkal S. et al. Impact of neurofibromatosis 1 upon quality of life in childhood: A cross-sectional study of 79 cases // Br J Dermatol. – 2009. – Vol. 160 (4). – Pp. 844–8. – https://doi.org/10.1111/j.1365-2133.2008.08949.x
  18. Wei G., Farooq J., Kumar A. Impact of mind-body treatment interventions on quality of life in neurofibromatosis patients: A systematic review and meta-analysis // Dermatol Ther. – 2021. – Vol. 34 (1). – e14613. – https://doi.org/10.1111/dth.14613
  19. Wolkenstein P., Zeller J., Revuz J. et al. Quality-of-life impairment in neurofibromatosis type 1: A cross-sectional study of 128 cases // Arch Dermatol. – 2001. – Vol. 137 (11). – Pp. 1421–5. – https://doi.org/10.1001/archderm.137.11.1421
  20. Granstrom S., Langenbruch A., Augustin M. et al. Psychological burden in adult neurofibromatosis type 1 patients: Impact of disease visibility on body image // Dermatology. – 2012. – Vol. 224 (2). – Pp. 160–167. – https://doi.org/10.1159/000337548
  21. Kanaya M.R., Greenberg J., Bakhshaie J. et al. Diverse learners: learning disabilities and quality of life following mind-body and health education interventions for adults with neurofibromatosis // J Neurooncol. – 2024. – Vol. 167 (2). – Pp. 315–322. – https://doi.org/10.1007/s11060-024-04610-9
  22. Sanagoo A., Jouybari L., Koohi F. et al. Evaluation of QoL in neurofibromatosis patients: A systematic review and meta-analysis study // BMC Neurol. – 2019. – Vol. 19 (1). – Art. 123. – https://doi.org/10.1186/s12883-019-1338-y
  23. Reichardt C., Scherwath A., Felix Mautner V. et al. Psychische Belastung von Erwachsenen mit Neurofibromatose Typ 1: Eine Längsschnittstudie [Psychological distress in adults with neurofibromatosis type 1: A longitudinal study] // Psychother Psychosom Med Psychol. – 2013. – Vol. 63 (2). – Pp. 85–92. – https://doi.org/10.1055/s-0032-1321883
  24. Wang D.L., Smith K.B., Esparza S. et al. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome // Genet Med. – 2012. – Vol. 14 (12). – Pp. 977–82. – https://doi.org/10.1038/gim.2012.85
  25. Bottesi G., Spoto A., Trevisson E. et al. Dysfunctional coping is related to impaired skin-related quality of life and psychological distress in patients with neurofibromatosis type 1 with major skin involvement // Br J Dermatol. – 2020. – Vol. 182 (6). – Pp. 1449–1457. – https://doi.org/10.1111/bjd.18363
  26. Bannon S.M., Hopkins S.W., Grunberg V.A. et al. Psychosocial profiles of risk and resiliency in neurofibromatoses: A person-centered analysis of illness adaptation // J Neurooncol. – 2022. – Vol. 156 (3). – Pp. 519–527. – https://doi.org/10.1007/s11060-021-03928-y
  27. Kaczorowski J.A., Smith T.F., Shrewsbury A.M. et al. Neurofibromatosis type 1 implicates ras pathways in the genetic architecture of neurodevelopmental disorders // Behav Genet. – 2020. – Vol. 50 (4). – Pp. 191–202. – https://doi.org/10.1007/s10519-020-09991-x
  28. Serur Y., Russo O., McGhee C.A. et al. Increased prevalence of psychiatric disorders in children with RASopathies: Comparing NF1, Noonan syndrome spectrum disorder, and the general population // Genes (Basel). – 2025. – Vol. 16 (7). – Art. 843. – https://doi.org/10.3390/genes16070843
  29. Crow A.J.D., Janssen J.M., Marshall C. et al. A systematic review and meta-analysis of intellectual, neuropsychological, and psychoeducational functioning in neurofibromatosis type 1 // Am J Med Genet A. – 2022. – Vol. 188 (8). – Pp. 2277–2292. – https://doi.org/10.1002/ajmg.a.62773
  30. Vogel A.C. Editorial: Understanding the nature of attention problems in neurofibromatosis type 1: Clinical and research implications // J Am Acad Child Adolesc Psychiatry. – 2025. – Vol. 64 (4). – Pp. 419–420. – https://doi.org/10.1016/j.jaac.2024.12.005
  31. Eijk S., Mous S.E., Dieleman G.C. et al. Autism spectrum disorder in an unselected cohort of children with neurofibromatosis type 1 (NF1) // J Autism Dev Disord. – 2018. – Vol. 48 (7). – Pp. 2278–2285. – https://doi.org/10.1007/s10803-018-3478-0
  32. Plasschaert E., Descheemaeker M.J., Van Eylen L. et al. Prevalence of autism spectrum disorder symptoms in children with neurofibromatosis type 1 // Am J Med Genet B Neuropsychiatr Genet. – 2015. – Vol. 168B (1). – Pp. 72–80. – https://doi.org/10.1002/ajmg.b.32280
  33. Morotti H., Mastel S., Keller K. et al. Autism and attention-deficit/hyperactivity disorders and symptoms in children with neurofibromatosis type 1 // Dev Med Child Neurol. – 2021. – Vol. 63 (2). – Pp. 226–232. – https://doi.org/10.1111/dmcn.14558
  34. Sanchez-Marco S.B., Lopez-Pison J., Serrano-Vinuales I. et al. Neurofibromatosis tipo 1 y trastorno por deficit de atencion. Nuestra experiencia actual [Neurofibromatosis type 1 and attention-deficit disorder. Our current experience] // Rev Neurol. – 2019. – Vol. 68 (1). – Pp. 7–10.
  35. Galasso C., Lo-Castro A., Di Carlo L. et al. Planning deficit in children with neurofibromatosis type 1: A neurocognitive trait independent from attention-deficit hyperactivity disorder (ADHD) // J Child Neurol. – 2014. – Vol. 29 (10). – Pp. 1320–6. – https://doi.org/10.1177/0883073813517001
  36. Hou Y., Yu L., Liu D. et al. Systematic review and meta-analysis: Attention-deficit/hyperactivity disorder symptoms in children with neurofibromatosis type 1 // J Am Acad Child Adolesc Psychiatry. – 2025. – Vol. 64 (4). – Pp. 447–462. – https://doi.org/10.1016/j.jaac.2024.09.011
  37. Saini L., Mukherjee S., Gunasekaran P.K. et al. Sleep problems in children with neurocutaneous syndromes: A cross-sectional study // J Child Neurol. – 2022. – Vol. 37 (10–11). – Pp. 864–870. – https://doi.org/10.1177/08830738221114560
  38. Kenborg L., Andersen E.W., Duun-Henriksen A.K. et al. Psychiatric disorders in individuals with neurofibromatosis 1 in Denmark: A nationwide register-based cohort study // Am J Med Genet A. – 2021. – Vol. 185 (12). – Pp. 3706–3716. – https://doi.org/10.1002/ajmg.a.62436
  39. Brar K.S., Trivedi C., Kaur N. et al. Prevalence of psychiatric comorbidities in patients with neurofibromatosis // Prim Care Companion CNS Disord. – 2023. – Vol. 25 (5). – 23m03514. – https://doi.org/10.4088/PCC.23m03514
  40. Baxter A.J., Scott K.M., Vos T. et al. Global prevalence of anxiety disorders: A systematic review and meta-regression // Psychol Med. – 2013. – Vol. 43 (5). – Pp. 897–910. – https://doi.org/10.1017/S003329171200147X
  41. Doser K., Andersen E.W., Kenborg L. et al. Clinical characteristics and quality of life, depression, and anxiety in adults with neurofibromatosis type 1: A nationwide study // Am J Med Genet A. – 2020. – Vol. 182 (7). – Pp. 1704–1715. – https://doi.org/10.1002/ajmg.a.61627
  42. Dance B., Dardare A., Fleming J. et al. The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1 // J Dermatol. – 2024. – Vol. 51 (8). – Pp. 1050–1059. – https://doi.org/10.1111/1346-8138.17276
  43. Yamauchi T., Suka M. Quality of life in patients with neurofibromatosis type 1: A nationwide database study in Japan from 2015 to 2019 // Environ Health Prev Med. – 2023. – Vol. 28. – Art. 77. – https://doi.org/10.1265/ehpm.23-00221
  44. Hamoy-Jimenez G., Kim R., Suppiah S. et al. Quality of life in patients with neurofibromatosis type 1 and 2 in Canada // Neurooncol Adv. – 2020. – Vol. 2, suppl. 1. – Pp. i141–i149. – https://doi.org/10.1093/noajnl/vdaa003
  45. Yoo H.K., Porteous A., Ng A. et al. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: A cross-sectional survey // BMC Neurol. – 2023. – Vol. 23 (1). – Art. 419. – https://doi.org/10.1186/s12883-023-03429-7
  46. Cohen J.S., Levy H.P., Sloan J. et al. Depression among adults with neurofibromatosis type 1: Prevalence and impact on quality of life // Clin Genet. – 2015. – Vol. 88 (5). – Pp. 425–30. – https://doi.org/10.1111/cge.12551
  47. Tang P.L., Wang H.H., Chou F.H. A Systematic review and meta-analysis of demoralization and depression in patients with cancer // Psychosomatics. – 2015. – Vol. 56. – Pp. 634–43. – https://doi.org/10.1016/j.psym.2015.06.005
  48. Belzeaux R., Lançon C. Neurofibromatose de type 1. Troubles psychiatriques et altération de la qualité de vie [Neurofibromatosis type 1: Psychiatric disorders and quality of life impairment] // Presse Med. – 2006. – Vol. 35 (2). – Pp. 277–80. – https://doi.org/10.1016/s0755-4982(06)74570-5
  49. Berardelli I., Maraone A., Belvisi D. et al. The importance of suicide risk assessment in patients affected by neurofibromatosis // Int J Psychiatry Clin Pract. – 2021. – Vol. 25 (4). – Pp. 350–355. – https://doi.org/10.1080/13651501.2021.1921217
  50. Lester E.G., Wang K.E., Blakeley J.O. et al. Occurrence and severity of suicidal ideation in adults with neurofibromatosis participating in a mind-body RCT // Cogn Behav Neurol. – 2023. – Vol. 36 (1). – Pp. 19–27. – https://doi.org/10.1097/WNN.0000000000000332
  51. Wiener L., Battles H., Bedoya S.Z. et al. Identifying symptoms of distress in youth living with neurofibromatosis type 1 (NF1) // J Genet Couns. – 2018. – Vol. 27 (1). – Pp. 115–123. – https://doi.org/10.1007/s10897-017-0128-1
  52. Armand M.L., Taieb C., Bourgeois A. et al. Burden of adult neurofibromatosis 1: Development and validation of a burden assessment tool // Orphanet J Rare Dis. – 2019. – Vol. 14 (1). – P. 94. – https://doi.org/10.1186/s13023-019-1067-8
  53. Payne J.M., Walsh K.S., Pride N.A. et al. Social skills and autism spectrum disorder symptoms in children with neurofibromatosis type 1: Evidence for clinical trial outcomes // Dev Med Child Neurol. – 2020. – Vol. 62 (7). – Pp. 813–819. – https://doi.org/10.1111/dmcn.14517
  54. Vranceanu A.M., Merker V.L., Plotkin S.R. et al. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: Results from a pilot study // J Neurooncol. – 2014. – Vol. 120 (1). – Pp. 103–9. – https://doi.org/10.1007/s11060-014-1522-2
  55. Vranceanu A.M., Manglani H.R., Choukas N.R. et al. Effect of mind-body skills training on quality of life for geographically diverse adults with neurofibromatosis: A fully remote randomized clinical trial // JAMA Netw Open. – 2023. – Vol. 6 (6). – e2320599. – https://doi.org/10.1001/jamanetworkopen.2023.20599
  56. D’Silva S., Poscablo C., Habousha R. et al. Mind-body medicine therapies for a range of depression severity: A systematic review // Psychosomatics. – 2012. – Vol. 53 (5). – Pp. 407–423. – https://doi.org/10.1016/j.psym.2012.04.006
  57. Lester E., DiStefano S., Mace R. et al. Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial // Gen Hosp Psychiatry. – 2020. – Vol. 62. – Pp. 72–78. – https://doi.org/10.1016/j.genhosppsych.2019.12.001
  58. Grunberg V.A., Bakhshaie J., Manglani H. et al. Mindfulness, coping, and optimism as mechanisms of change in the 3RP-NF intervention // J Clin Psychol. – 2024. – Vol. 80 (2). – Pp. 456–470. – https://doi.org/10.1002/jclp.23623
  59. McDermott K., Bakhshaie J., Brewer J. et al. The impact of a virtual mind-body program on symptoms of depression and anxiety among international English-speaking adults with neurofibromatosis // Am J Med Genet A. – 2024. – Vol. 194 (6). – e63543. – https://doi.org/10.1002/ajmg.a.63543
  60. Yoncheva Y.N., Hardy K.K., Lurie D.J. et al. Computerized cognitive training for children with neurofibromatosis type 1: A pilot resting-state fMRI study // Psychiatry Res Neuroimaging. – 2017. – Vol. 266. – Pp. 53–58. – https://doi.org/10.1016/j.pscychresns.2017.06.003
  61. Martin S., Wolters P.L., Toledo-Tamula M.A. et al. Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy // Am J Med Genet A. – 2016. – Vol. 170 (6). – Pp. 1462–70. – https://doi.org/10.1002/ajmg.a.37623
  62. Torres Nupan M.M., Velez Van Meerbeke A., Lopez Cabra C.A., Herrera Gomez P.M. Cognitive and behavioral disorders in children with neurofibromatosis type 1 // Front Pediatr. – 2017. – Vol. 5. – Art. 227. – https://doi.org/10.3389/fped.2017.00227
  63. Sato A. mTOR, a potential target to treat autism spectrum disorder // CNS Neurol Disord Drug Targets. 2016. – Vol. 15 (5). – Pp. 533–43. – https://doi.org/10.2174/1871527315666160413120638

Downloads

Download data is not yet available.